BMY•benzinga•
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
Summary
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga